EBR Systems Surpasses 100 WiSE Implants with Major US Healthcare Contracts
4 min read
8:25am on Wednesday 12th of August, 2026 AEST ~8am, 12th Aug, 26
Popular on LinkedIn
EBR Systems marked a commercial milestone with over 100 WiSE CRT implants and secured purchasing agreements with three major US healthcare networks. The company is progressing toward Medicare coverage and scaling manufacturing, supported by a near-complete A$150 million capital raise.
- Surpassed 100 commercial WiSE implants
- Secured purchasing agreements with HCA, Advocate Health, CHRISTUS Health
- CMS initiated National Coverage Determination for WiSE
- Transitioning to larger Santa Clara manufacturing facility
- Completed majority of A$150 million capital raise
Commercial Momentum Accelerates with Over 100 WiSE Implants
EBR Systems (ASX:EBR) has crossed a significant commercial threshold, surpassing 100 wireless cardiac resynchronization therapy (CRT) implants using its WiSE System. During Q2 2026 alone, 46 implants were completed across 23 US hospitals, with multiple sites performing their first and subsequent implants. Physician training continues to expand rapidly, with 90 physicians across 30 sites now credentialed to perform WiSE implants, including 26 trained in the quarter.
The company’s disciplined rollout strategy focuses on physician experience and hospital workflow optimization, aiming to build a foundation for broader adoption. This measured approach is reflected in the steady increase in purchase agreements, with 17 new contracts signed in Q2, adding to 35 previously secured, and major deals inked with HCA Healthcare, Advocate Health, and CHRISTUS Health. These agreements open purchasing pathways across nearly 325 hospitals spanning 35 states, significantly boosting EBR’s commercial infrastructure.
CMS Advances Medicare Coverage Review
Manufacturing Scale-Up Underway with New Facility Transition
EBR is on track to complete the transition of manufacturing operations from its legacy Sunnyvale facility to a new, larger site in Santa Clara by the end of 2026. The new facility is over three times bigger and designed to support increased production capacity and efficiency gains. Early administrative moves into the Santa Clara premises have commenced, with full manufacturing contingent on FDA certification. The company anticipates gross margins will improve as more manufacturing processes are brought in-house.
Capital Raise Strengthens Balance Sheet Amid Cash Burn
To fuel its commercial scale-up and progress toward cash flow breakeven, EBR has executed a fully underwritten A$150 million capital raise, with A$115 million completed and the remaining A$35 million tranche expected by 24 August 2026. The raise has bolstered the company’s cash, cash equivalents, restricted cash, and marketable securities to approximately US$89.5 million (A$130.1 million) as of 30 June 2026. Despite this, EBR reported a net loss of US$17.5 million for Q2 2026, reflecting increased sales and marketing investments and manufacturing scale-up costs.
Investigation Confirms Isolated Device Complications
Following two reported complications during post-procedure echocardiograms, EBR conducted an internal investigation which concluded the events were isolated and not related to the device’s performance. The company noted that appropriate device labelling and imaging protocols mitigate these risks. Importantly, these incidents have not affected implant rates at other sites, supporting the ongoing commercial momentum.
Financials Reflect Growing Commercial Activity and Investment
Revenue for Q2 2026 rose sharply to US$2.6 million from US$170,000 a year earlier, driven by increased implant volume and hospital adoption. Gross margin improved to 13%, up from 7.8% in the prior quarter, aided by higher average selling prices and manufacturing efficiencies, though still impacted by legacy clinical trial inventory usage. Operating expenses rose substantially, with research and development costs up 11.2% and selling, general and administrative expenses nearly doubling due to expanded sales efforts and infrastructure costs.
The company’s cash burn remains significant, with operating cash outflows of US$17.2 million in Q2 2026. EBR holds $41.8 million of debt maturing within 12 months and acknowledges substantial doubt about its ability to continue as a going concern without further financing. The capital raise and expected debt refinancing are critical to sustaining operations.
Bottom Line?
EBR’s commercial and regulatory advances position it for growth, but the company’s financial runway hinges on completing its capital raise and securing Medicare coverage.
Questions in the middle?
- Will the CMS National Coverage Determination in March 2027 provide the reimbursement clarity WiSE needs for broader adoption?
- How swiftly can EBR scale manufacturing in Santa Clara to meet growing US demand while improving gross margins?
- What impact might the recent device complications have on physician confidence and patient uptake over the longer term?
